Our Global Managed
Access Program
Agios is committed to improving the lives of individuals affected by life-altering rare diseases through programs that provide support throughout their journey and help patients and their families explore and access available treatment options.
Our Global Managed Access Program (GMAP) offers a pathway for patients to obtain access to PYRUKYND® (mitapivat) provided they meet the defined criteria and reside in a country where access is permissible under local laws and regulations.
Healthcare providers may submit an inquiry on behalf of their patient to Agios for consideration.
Agios will evaluate all requests in a fair and equitable manner and in consultation with qualified treating healthcare providers. Requests will be acknowledged within two business days of receipt.